Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-
– Treatment with the once-daily vanza triple CFTR modulator regimen met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older –– Results were more pronounced in the single-arm study in children ages 6 to 11 years, demonstrating the potential that treati...
Source: pharmiweb.com